WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · HB 448

Legislative bill overview

HB 448 would require prescription drug rebates negotiated between pharmaceutical manufacturers and insurance companies to be applied directly to patient cost-sharing amounts (copayments, coinsurance, deductibles) rather than being retained by insurers or pharmacy benefit managers. This means patients would see immediate out-of-pocket savings when purchasing medications, with rebates reducing their actual costs at the pharmacy counter.

Why is this important

Prescription drug costs remain a major burden for Ohio patients, with many unable to afford medications despite having insurance. Currently, rebates—which can be substantial—often benefit insurers' bottom lines rather than patient wallets. Applying rebates to cost-sharing would provide tangible relief at the point of sale and increase medication affordability and adherence for patients managing chronic conditions.

Potential points of contention

  • Insurance industry opposition: Insurers and pharmacy benefit managers argue rebates help them negotiate lower drug prices; redirecting rebates to patients could reduce their negotiating leverage and lead to higher base prices from manufacturers
  • Implementation complexity: Determining how to apply variable rebates to cost-sharing in real-time at pharmacy systems presents technical and administrative challenges
  • Market effects uncertainty: Critics worry this could disrupt the current rebate system without guaranteeing lower drug prices overall, potentially shifting costs elsewhere in the healthcare system

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.